Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge

Amiodarone is an iodine-based, potent antiarrhythmic drug bearing a structural resemblance to thyroxine (T4). It is known to produce thyroid abnormalities ranging from abnormal thyroid function testing to overt hypothyroidism or hyperthyroidism. These adverse effects may occur in patients with or wi...

Full description

Bibliographic Details
Main Authors: Umang Barvalia, Barkha Amlani, Ram Pathak
Format: Article
Language:English
Published: Hindawi Limited 2014-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2014/231651
id doaj-5fb9bc4a3d8343d2adad2606da0a7b58
record_format Article
spelling doaj-5fb9bc4a3d8343d2adad2606da0a7b582020-11-24T23:12:21ZengHindawi LimitedCase Reports in Medicine1687-96271687-96352014-01-01201410.1155/2014/231651231651Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic ChallengeUmang Barvalia0Barkha Amlani1Ram Pathak2Department of Internal Medicine, Marshfield Clinic, 1000 N. Oak Avenue, Marshfield, WI 54449, USADepartment of Internal Medicine, Marshfield Clinic, 1000 N. Oak Avenue, Marshfield, WI 54449, USADepartment of Endocrinology, Marshfield Clinic, Marshfield, WI 54449, USAAmiodarone is an iodine-based, potent antiarrhythmic drug bearing a structural resemblance to thyroxine (T4). It is known to produce thyroid abnormalities ranging from abnormal thyroid function testing to overt hypothyroidism or hyperthyroidism. These adverse effects may occur in patients with or without preexisting thyroid disease. Amiodarone-induced thyrotoxicosis (AIT) is a clinically recognized condition commonly due to iodine-induced excessive synthesis of thyroid, also known as type 1 AIT. In rare instances, AIT is caused by amiodarone-induced inflammation of thyroid tissue, resulting in release of preformed thyroid hormones and a hyperthyroid state, known as type 2 AIT. Distinguishing between the two states is important, as both conditions have different treatment implications; however, a mixed presentation is not uncommon, posing diagnostic and treatment challenges. We describe a case of a patient with amiodarone-induced type 2 hyperthyroidism and review the current literature on the best practices for diagnostic and treatment approaches.http://dx.doi.org/10.1155/2014/231651
collection DOAJ
language English
format Article
sources DOAJ
author Umang Barvalia
Barkha Amlani
Ram Pathak
spellingShingle Umang Barvalia
Barkha Amlani
Ram Pathak
Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge
Case Reports in Medicine
author_facet Umang Barvalia
Barkha Amlani
Ram Pathak
author_sort Umang Barvalia
title Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge
title_short Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge
title_full Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge
title_fullStr Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge
title_full_unstemmed Amiodarone-Induced Thyrotoxic Thyroiditis: A Diagnostic and Therapeutic Challenge
title_sort amiodarone-induced thyrotoxic thyroiditis: a diagnostic and therapeutic challenge
publisher Hindawi Limited
series Case Reports in Medicine
issn 1687-9627
1687-9635
publishDate 2014-01-01
description Amiodarone is an iodine-based, potent antiarrhythmic drug bearing a structural resemblance to thyroxine (T4). It is known to produce thyroid abnormalities ranging from abnormal thyroid function testing to overt hypothyroidism or hyperthyroidism. These adverse effects may occur in patients with or without preexisting thyroid disease. Amiodarone-induced thyrotoxicosis (AIT) is a clinically recognized condition commonly due to iodine-induced excessive synthesis of thyroid, also known as type 1 AIT. In rare instances, AIT is caused by amiodarone-induced inflammation of thyroid tissue, resulting in release of preformed thyroid hormones and a hyperthyroid state, known as type 2 AIT. Distinguishing between the two states is important, as both conditions have different treatment implications; however, a mixed presentation is not uncommon, posing diagnostic and treatment challenges. We describe a case of a patient with amiodarone-induced type 2 hyperthyroidism and review the current literature on the best practices for diagnostic and treatment approaches.
url http://dx.doi.org/10.1155/2014/231651
work_keys_str_mv AT umangbarvalia amiodaroneinducedthyrotoxicthyroiditisadiagnosticandtherapeuticchallenge
AT barkhaamlani amiodaroneinducedthyrotoxicthyroiditisadiagnosticandtherapeuticchallenge
AT rampathak amiodaroneinducedthyrotoxicthyroiditisadiagnosticandtherapeuticchallenge
_version_ 1725601221493915648